Active, Not Recruiting
Continuing Treatment for Subjects Who Have Participated in a Prior Protocol Investigating Elotuzumab - CA204-185
Atualizado: 25 julho, 2024 | ClinicalTrials.gov
Fase
Gênero(s)
Faixa etária
Active, Not Recruiting
For more information regarding Bristol Myers Squibb Clinical Trial participation, please visit www.BMSStudyConnect.com Inclusion Criteria: - Participated in a previous elotuzumab protocol (including, but not limited to HuLuc63-1703, CA204007, CA204009, or CA204011) and is deemed by the investigator to be deriving benefit from elotuzumab and/or other study drugs as defined by the previous protocol - Receiving elotuzumab and/or other study drugs at the time of signature of informed consent - Males and Females, ages 18 and older Exclusion Criteria: - All subjects previously discontinued from an elotuzumab study for any reason - Subjects not receiving clinical benefit from previous study therapy - Subjects who are not medically well enough to receive study therapy as determined by the investigator Other protocol defined inclusion/exclusion criteria could apply
É altamente recomendável que você entre em contato com a BMS para relatar efeitos colaterais (eventos adversos).
Efeitos colaterais (eventos adversos) e outros eventos relatáveis estão definidos aqui.
Relate efeitos colaterais (eventos adversos) ou reclamações sobre a qualidade do produto: Informações médicas
